Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

Even if wild-type and -negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably occurs. Mechanisms of resistance to EGFR blockade include the emergence of , , and extracellular domain mutations as well as alterations. However,...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research 2017-05, Vol.23 (10), p.2414-2422
Main Authors:	Pietrantonio, Filippo, Vernieri, Claudio, Siravegna, Giulia, Mennitto, Alessia, Berenato, Rosa, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Lonardi, Sara, Morano, Federica, Picciani, Benedetta, Busico, Adele, Volpi, Chiara Costanza, Martinetti, Antonia, Battaglin, Francesca, Bossi, Ilaria, Pellegrinelli, Alessio, Milione, Massimo, Cremolini, Chiara, Di Bartolomeo, Maria, Bardelli, Alberto, de Braud, Filippo
Format:	Article
Language:	eng
Subjects:	Adult Aged Amplification Antibodies, Monoclonal, Humanized - administration & dosage Biomarkers, Tumor - blood Blood Cancer Circulating Tumor DNA - blood Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Complexity Disease-Free Survival Drug Resistance, Neoplasm - genetics Emergence Epidermal growth factor receptors ErbB-2 protein Evolution Experimental design Female GTP Phosphohydrolases - genetics Heterogeneity Humans K-Ras protein Male Membrane Proteins - genetics Metastases Metastasis Middle Aged Monoclonal antibodies Mutation Neoplasm Metastasis Patients Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins c-met - genetics Proto-Oncogene Proteins p21(ras) - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Receptor, ErbB-2 - genetics Silver Tissue analysis Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Even if wild-type and -negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably occurs. Mechanisms of resistance to EGFR blockade include the emergence of , , and extracellular domain mutations as well as alterations. However, these findings derive from retrospective studies that analyzed one single resistance mechanism at a time; moreover, it is still unclear how molecular heterogeneity affects clonal evolution in patients. In this work, we aimed at extensively characterizing and correlating the molecular characteristics of tissue- and blood-based data in a prospective cohort of patients with mCRC who received anti-EGFR antibodies. Twenty-two - wild-type, -negative mCRC patients progressing on anti-EGFR therapy after initial response underwent rebiopsy. Next-generation sequencing and silver hybridization (SISH)/IHC analyses were performed both on archival tumors and postprogression samples. Circulating tumor (ctDNA) molecular profiles were obtained in matched tissue-plasma samples. mutations and amplification were the most frequently detected resistance mechanisms in both tissue and blood sample analysis. On the other hand, and ectodomain mutations were much rarer. Patients with acquired amplification showed worse PFS on anti-EGFRs. We detected both intralesion heterogeneity, as suggested by co-occurrence of different resistance mechanisms in the same sample, and interlesion heterogeneity. The combined analysis of tissue and blood (ctDNA) results highlights the complexity of clonal evolution triggered by EGFR blockade. Our results indicate that it may be extremely challenging to target the complex landscape of molecular heterogeneity associated with emergence of resistance to targeted therapies in patients with mCRC. .
ISSN:	1078-0432 1557-3265